HEALEY ALS Platform Trial Ancillary Study Policy

Approvals & Revision History

Healey Center for ALS at Massachusetts General Hospital (MGH)
This Ancillary Study Policy has been reviewed and approved by:

Merit Cudkowicz, MD, MSc.
Study Principal Investigator and IND Holder

<table>
<thead>
<tr>
<th>Name &amp; Title</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabrina Paganoni, MD, PhD.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study co-Investigator</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Revision History

<table>
<thead>
<tr>
<th>VERSION / DATE</th>
<th>DESCRIPTION OF CHANGE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1.0 June 30, 2020</td>
<td>Original</td>
</tr>
</tbody>
</table>

PURPOSE:
To describe the HEALEY ALS Platform Trial Ancillary Study Policy on reviewing and approving ancillary studies.

POLICY:
The primary goal of HEALEY ALS Platform Trial is to successfully plan, conduct, analyze, and report primary results from each Regimen Specific Appendix (RSA) conducted under the platform trial. There are often opportunities to conduct additional studies to further our scientific understanding related ALS and therapies studied. These add-on studies can leverage the effort and finances already being spent on the platform trial. However, they also have the potential to detract focus from the primary goal of the HEALEY ALS Platform Trial. Consideration of add-on studies need to balance the academic opportunities to leverage an established clinical trial with the need to ensure the successful execution of that clinical trial.

DEFINITIONS:
For the purposes of this document, an Ancillary Study is a study that requires use of any HEALEY ALS Platform Trial participants or resources for a purpose external to any of the main aims outlined in the Master Protocol. Resources include staff effort and resources at the HEALEY Center Clinical Coordinating Center, Data Coordinating Center (DCC), other parties (i.e. vendors) and clinical sites, as well as financial support.
PROCEDURE:

i.) Proposal Submission:
A formal proposal is required for all HEALEY ALS Platform Trial Ancillary Study requests. The outline guide in Appendix I describes the information that should be submitted to propose an Ancillary Study. It is important that each of the points in this outline be addressed. The completed proposal should be submitted to HealeyCenterforALS@MGH.HARVARD.EDU for circulation and review of proposals.

ii.) Proposal Review:
The HEALEY ALS Platform Trial Sponsor (Principal Investigator) and co-Principal Investigator will conduct an initial review of all proposals. If the proposal is deemed potentially feasible, they will assign reviewers from the HEALEY ALS Platform Trial Design Committee to review the proposal. If needed, the Trial Design Committee will discuss the proposal during a meeting of this committee. Depending on request, other members of HEALEY ALS Platform Trial team may be asked to weigh in on impact on study. If recommended for approval, the HEALEY ALS Platform Trial PI or Co-PI will take the proposal to the HEALEY ALS Platform Trial Executive Committee for review and final approval by majority of members.

iii.) Review Criteria:
Factors to be considered in proposal review include:
   a.) potential scientific contribution of the proposed ancillary study;
   b.) level of difficulty in conducting the proposed ancillary study;
   c.) potential disruption in the conduct of the primary study;
   d.) financial cost and available funding for the proposed ancillary study;
   e.) other issues, as identified during the review process.
Appendix I. HEALEY ALS Platform Trial Ancillary Study
Proposal Outline Guide

I. Regimen or Master
   a. Regimen or Master Protocol to which this protocol will be added
   b. Investigator sponsoring the ancillary study

II. Investigative Team
   a. List of Study investigators and description of their contributions to the study, with copies of their CVs

III. Protocol (Requires the following information. May submit a formal protocol if available.)
   a. Specific Aims
   b. Background and Significance
   c. Preliminary Studies
   d. Experimental Design
      i. Inclusion/Exclusion Criteria (Study population) if different
      ii. Endpoints and time points
      iii. Methods for any additional assessments
   e. Statistical and Data Management Considerations
   f. Statistical methods
      ii. Sample size and power or precision justification
   g. Data Collection Needs

IV. Participant considerations
   a. Additional risk to the participants
   b. How will the additional risks be recognized and minimized
   c. Additional burden to the participants
   d. Need for changes/additions to be added to the Informed Consent Form

V. Effect Schedule of Activities/study visits
   a. Additional assessments (If yes, explain and justify)
   b. Additional visits or time required to complete additional assessments
   c. Additional laboratory assessments (If yes, explain and justify)
   d. Additional time and processing required for new laboratory assessments
   e. Other

VI. Required Resources (Please describe who will be responsible for supplying these resources and who will be responsible for the costs associated with these additional requirements)
   a. Additional burden on me/effort on Healey Site staff (time and cost associated with per participant fee)
   b. Participate reimbursement (if applicable)
   c. Additional time/effort on site investigators and staff
   d. Additional time/effort on local laboratories
e. Additional regulatory submissions (cIRB and FDA) required
f. Additional time/effort on others

VII. Effects on the Coordination Centers or other parties (Please describe the additional requirements in the following areas and who will be responsible for the real or indirect costs associated with these requirements)
   a. Additional regulatory oversight
   b. Additional safety (SAE) oversight
   c. Additional DSMB oversight
   d. Additional central laboratories requirements
   e. Additional sample collection kits and supplies
   f. Additional data acquisition and database requirements
   g. Additional statistical analysis and reporting requirements

VIII. References Cited